Nebenwirkungen · Steglatro
Steglatro 5 mg film-coated tablets Steglatro 15 mg film-coated tablets · Abschnitt 4.8 · PDF-Seite 8
HOS-137640 · Präparat HOS-098083
The safety and tolerability of ertugliflozin were assessed in 7 placebo- or active comparator-controlled studies with a total of 3 409 patients with type 2 diabetes mellitus treated with ertugliflozin 5 mg or 15 mg. In addition, the safety and tolerability of ertugliflozin in patients with type 2 diabetes and established atherosclerotic cardiovascular disease were assessed in VERTIS CV (see section 5.1) with a total of 5 493 patients treated with ertugliflozin 5 mg or 15 mg and a mean duration of exposure of 2.9 years.
Originalpassage; keine automatisch abgeleitete Schwere, Häufigkeit oder Kausalität. Auch verneinte Befunde und nicht untersuchte Kombinationen bleiben sichtbar.
Vollständigen Kontext in der EMA-Fachinformation lesen →Quellennachweis
Version 2025-11-21T02:00:00Z · SHA-256 5baeb717396c9983a8fe8fdd9275ddd5dee36f5f706f04ce7ca090a915f2b671 · Passage 8be5703ec5bfc27adabeb0c8a33817856101e9f78664ca00507ec713c11c1fbb · Zeichen 31–555 im Abschnitt